Immunogenetics of autoimmune thyroid diseases: A comprehensive review

Journal of Autoimmunity

Volumn 64, Issue , 2015, Pages 82-90

  Lee, Hanna J ^a   Li, Cheuk Wun ^a   Hammerstad, Sara Salehi ^a,b   Stefan, Mihaela ^a   Tomer, Yaron ^a,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Autoimmune thyroid disease; Autoimmunity; Graves' disease; Hashimoto's thyroiditis; Immunogenetics; Polymorphism

Indexed keywords

CD40 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA DR3 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; NOTCH4 RECEPTOR; THYROID ANTIBODY; THYROTROPIN RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; AUTOIMMUNE THYROIDITIS; CELL INTERACTION; ETHNIC GROUP; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GRAVES DISEASE; HUMAN; HYPOTHYROIDISM; IMMUNOGENETICS; IMMUNOLOGICAL SYNAPSE; IMMUNOLOGICAL TOLERANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION; ANIMAL; AUTOIMMUNE DISEASE; GENE LOCUS; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; METABOLISM; PHENOTYPE; THYROID DISEASES;

ANIMALS; ANTIGEN PRESENTATION; AUTOIMMUNE DISEASES; GENETIC LOCI; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNE TOLERANCE; IMMUNOGENETICS; PHENOTYPE; THYROID DISEASES;

EID: 84946471067     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2015.07.009     Document Type: Review

References (130)

1. Jacobson D.L., Gange S.J., Rose N.R., Graham N.M. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 1997, 84:223-243.
2. Antonelli A., Ferrari S.M., Corrado A., Di Domenicantonio A., Fallahi P. Autoimmune thyroid disorders. Autoimmun. Rev. 2015, 14:174-180.
3. Tomer Y. Mechanisms of autoimmune thyroid diseases: from genetics to epigenetics. Annu. Rev. Pathol. 2014, 9:147-156.
4. Villanueva R., Greenberg D.A., Davies T.F., Tomer Y. Sibling recurrence risk in autoimmune thyroid disease. Thyroid Off. J. Am. Thyroid Assoc. 2003, 13:761-764.
5. Tomer Y., Davies T.F. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocr. Rev. 2003, 24:694-717.
6. Hall R., Stanbury J.B. Familial studies of autoimmune thyroiditis. Clin. Exp. Immunol. 1967, 2(Suppl.):719-725.
7. Brix T.H., Christensen K., Holm N.V., Harvald B., Hegedus L. A population-based study of Graves' disease in Danish twins. Clin. Endocrinol. 1998, 48:397-400.
8. Brix T.H., Hegedus L. Twin studies as a model for exploring the aetiology of autoimmune thyroid disease. Clin. Endocrinol. 2012, 76:457-464.
9. Brix T.H., Kyvik K.O., Christensen K., Hegedus L. Evidence for a major role of heredity in Graves' disease: a population-based study of two Danish twin cohorts. J. Clin. Endocrinol. Metab. 2001, 86:930-934.
10. McLeod D.S., Cooper D.S., Ladenson P.W., Whiteman D.C., Jordan S.J. Race/Ethnicity and the prevalence of thyrotoxicosis in young americans. Thyroid Off. J. Am. Thyroid Assoc. 2015, 25:621-628.
11. Dechairo B.M., Zabaneh D., Collins J., Brand O., Dawson G.J., Green A.P., et al. Association of the TSHR gene with Graves' disease: the first disease specific locus. Eur. J. Hum. Genet. EJHG 2005, 13:1223-1230.
12. Brand O.J., Barrett J.C., Simmonds M.J., Newby P.R., McCabe C.J., Bruce C.K., et al. Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves' disease. Hum. Mol. Genet. 2009, 18:1704-1713.
13. Chu X., Pan C.M., Zhao S.X., Liang J., Gao G.Q., Zhang X.M., et al. A genome-wide association study identifies two new risk loci for Graves' disease. Nat. Genet. 2011, 43:897-901.
14. Ploski R., Brand O.J., Jurecka-Lubieniecka B., Franaszczyk M., Kula D., Krajewski P., et al. Thyroid stimulating hormone receptor (TSHR) intron 1 variants are major risk factors for Graves' disease in three European Caucasian cohorts. PLoS One 2010, 5:e15512.
15. Tomer Y., Hasham A., Davies T.F., Stefan M., Concepcion E., Keddache M., et al. Fine mapping of loci linked to autoimmune thyroid disease identifies novel susceptibility genes. J. Clin. Endocrinol. Metab. 2013, 98:E144-E152.
16. Stefan M., Wei C., Lombardi A., Li C.W., Concepcion E.S., Inabnet W.B., et al. Genetic-epigenetic dysregulation of thymic TSH receptor gene expression triggers thyroid autoimmunity. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:12562-12567.
17. Colobran R., Armengol Mdel P., Faner R., Gartner M., Tykocinski L.O., Lucas A., et al. Association of an SNP with intrathymic transcription of TSHR and Graves' disease: a role for defective thymic tolerance. Hum. Mol. Genet. 2011, 20:3415-3423.
18. + Tregs. J. Clin. Invest. 2005, 115:3276-3284.
19. Kaufmann E., Knochel W. Five years on the wings of fork head. Mech. Dev. 1996, 57:3-20.
20. Brunkow M.E., Jeffery E.W., Hjerrild K.A., Paeper B., Clark L.B., Yasayko S.A., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 2001, 27:68-73.
21. Schubert L.A., Jeffery E., Zhang Y., Ramsdell F., Ziegler S.F. Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. J. Biol. Chem. 2001, 276:37672-37679.
22. Wu Y., Borde M., Heissmeyer V., Feuerer M., Lapan A.D., Stroud J.C., et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006, 126:375-387.
23. Marson A., Kretschmer K., Frampton G.M., Jacobsen E.S., Polansky J.K., MacIsaac K.D., et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007, 445:931-935.
24. Zheng Y., Josefowicz S.Z., Kas A., Chu T.T., Gavin M.A., Rudensky A.Y. Genome-wide analysis of Foxp3 target genes in developing and mature regulatory T cells. Nature 2007, 445:936-940.
25. Ono M., Yaguchi H., Ohkura N., Kitabayashi I., Nagamura Y., Nomura T., et al. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature 2007, 446:685-689.
26. Camperio C., Caristi S., Fanelli G., Soligo M., Del Porto P., Piccolella E. Forkhead transcription factor FOXP3 upregulates CD25 expression through cooperation with RelA/NF-kappaB. PLoS One 2012, 7:e48303.
27. Maloy K.J., Powrie F. Regulatory T cells in the control of immune pathology. Nat. Immunol. 2001, 2:816-822.
28. Sakaguchi S., Sakaguchi N., Shimizu J., Yamazaki S., Sakihama T., Itoh M., et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 2001, 182:18-32.
29. Chatila T.A., Blaeser F., Ho N., Lederman H.M., Voulgaropoulos C., Helms C., et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J. Clin. Invest. 2000, 106:R75-R81.
30. Bennett C.L., Christie J., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 2001, 27:20-21.
31. Wildin R.S., Ramsdell F., Peake J., Faravelli F., Casanova J.L., Buist N., et al. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 2001, 27:18-20.
32. Wildin R.S., Freitas A. IPEX and FOXP3: clinical and research perspectives. J. Autoimmun. 2005, (25 Suppl.):56-62.
33. Katoh H., Zheng P., Liu Y. FOXP3: genetic and epigenetic implications for autoimmunity. J. Autoimmun. 2013, 41:72-78.
34. Ban Y., Tozaki T., Tobe T., Ban Y., Jacobson E.M., Concepcion E.S., et al. The regulatory T cell gene FOXP3 and genetic susceptibility to thyroid autoimmunity: an association analysis in Caucasian and Japanese cohorts. J. Autoimmun. 2007, 28:201-207.
35. Inoue N., Watanabe M., Morita M., Tomizawa R., Akamizu T., Tatsumi K., et al. Association of functional polymorphisms related to the transcriptional level of FOXP3 with prognosis of autoimmune thyroid diseases. Clin. Exp. Immunol. 2010, 162:402-406.
36. Villano M.J., Huber A.K., Greenberg D.A., Golden B.K., Concepcion E., Tomer Y. Autoimmune thyroiditis and diabetes: dissecting the joint genetic susceptibility in a large cohort of multiplex families. J. Clin. Endocrinol. Metab. 2009, 94:1458-1466.
37. Jenkins R.C., Weetman A.P. Disease associations with autoimmune thyroid disease. Thyroid Off. J. Am. Thyroid Assoc. 2002, 12:977-988.
38. Pagani F., Buratti E., Stuani C., Romano M., Zuccato E., Niksic M., et al. Splicing factors induce cystic fibrosis transmembrane regulator exon 9 skipping through a nonevolutionary conserved intronic element. J. Biol. Chem. 2000, 275:21041-21047.
39. 2+ exchanger intron 2 activates splicing. Eur. J. Biochem. FEBS 2001, 268:1076-1083.
40. Li C.W., Concepcion E., Tomer Y. Dissecting the role of the FOXP3 gene in the joint genetic susceptibility to autoimmune thyroiditis and diabetes: a genetic and functional analysis. Gene 2015, 556:142-148.
41. Cerosaletti K., Schneider A., Schwedhelm K., Frank I., Tatum M., Wei S., et al. Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients. PLoS One 2013, 8:e83811.
42. Bayer A.L., Yu A., Adeegbe D., Malek T.R. Essential role for interleukin-2 for CD4(+)CD25(+) T regulatory cell development during the neonatal period. J. Exp. Med. 2005, 201:769-777.
43. Brand O.J., Lowe C.E., Heward J.M., Franklyn J.A., Cooper J.D., Todd J.A., et al. Association of the interleukin-2 receptor alpha (IL-2Ralpha)/CD25 gene region with Graves' disease using a multilocus test and tag SNPs. Clin. Endocrinol. 2007, 66:508-512.
44. Cooper J.D., Simmonds M.J., Walker N.M., Burren O., Brand O.J., Guo H., et al. Seven newly identified loci for autoimmune thyroid disease. Hum. Mol. Genet. 2012, 21:5202-5208.
45. Chistiakov D.A., Chistiakova E.I., Voronova N.V., Turakulov R.I., Savost'anov K.V. A variant of the Il2ra/Cd25 gene predisposing to graves' disease is associated with increased levels of soluble interleukin-2 receptor. Scand. J. Immunol. 2011, 74:496-501.
46. Reiser H., Stadecker M.J. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N. Engl. J. Med. 1996, 335:1369-1377.
47. Teft W.A., Kirchhof M.G., Madrenas J. A molecular perspective of CTLA-4 function. Annu. Rev. Immunol. 2006, 24:65-97.
48. Munroe M.E. Functional roles for T cell CD40 in infection and autoimmune disease: the role of CD40 in lymphocyte homeostasis. Semin. Immunol. 2009, 21:283-288.
49. Faure G.C., Bensoussan-Lejzerowicz D., Bene M.C., Aubert V., Leclere J. Coexpression of CD40 and class II antigen HLA-DR in Graves' disease thyroid epithelial cells. Clin. Immunol. Immunopathol. 1997, 84:212-215.
50. Toubi E., Shoenfeld Y. The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway. Autoimmunity 2004, 37:457-464.
51. Bishop G.A., Hostager B.S. The CD40-CD154 interaction in B cell-T cell liaisons. Cytokine Growth Factor Rev. 2003, 14:297-309.
52. Bishop G.A. The many faces of CD40: multiple roles in normal immunity and disease. Semin. Immunol. 2009, 21:255-256.
53. Carayanniotis G., Masters S.R., Noelle R.J. Suppression of murine thyroiditis via blockade of the CD40-CD40L interaction. Immunology 1997, 90:421-426.
54. Kehry M.R. CD40-mediated signaling in B cells. Balancing cell survival, growth, and death. J. Immunol. 1996, 156:2345-2348.
55. Tomer Y., Concepcion E., Greenberg D.A. A C/T single-nucleotide polymorphism in the region of the CD40 gene is associated with Graves' disease. Thyroid Off. J. Am. Thyroid Assoc. 2002, 12:1129-1135.
56. Kurylowicz A., Kula D., Ploski R., Skorka A., Jurecka-Lubieniecka B., Zebracka J., et al. Association of CD40 gene polymorphism (C-1T) with susceptibility and phenotype of Graves' disease. Thyroid Off. J. Am. Thyroid Assoc. 2005, 15:1119-1124.
57. Ban Y., Tozaki T., Taniyama M., Tomita M., Ban Y. Association of a C/T single-nucleotide polymorphism in the 5' untranslated region of the CD40 gene with Graves' disease in Japanese. Thyroid Off. J. Am. Thyroid Assoc. 2006, 16:443-446.
58. Kim T.Y., Park Y.J., Hwang J.K., Song J.Y., Park K.S., Cho B.Y., et al. A C/T polymorphism in the 5'-untranslated region of the CD40 gene is associated with Graves' disease in Koreans. Thyroid Off. J. Am. Thyroid Assoc. 2003, 13:919-925.
59. Jacobson E.M., Huber A.K., Akeno N., Sivak M., Li C.W., Concepcion E., et al. A CD40 Kozak sequence polymorphism and susceptibility to antibody-mediated autoimmune conditions: the role of CD40 tissue-specific expression. Genes Immun. 2007, 8:205-214.
60. Mukai T., Hiromatsu Y., Fukutani T., Ichimura M., Kaku H., Miyake I., et al. A C/T polymorphism in the 5' untranslated region of the CD40 gene is associated with later onset of Graves' disease in Japanese. Endocr. J. 2005, 52:471-477.
61. Hsiao J.Y., Hsieh M.C., Hsiao C.T., Weng H.H., Ke D.S. Association of CD40 and thyroglobulin genes with later-onset Graves' disease in Taiwanese patients. Eur. J. Endocrinol. European Fed. Endocr. Soc. 2008, 159:617-621.
62. Huber A.K., Finkelman F.D., Li C.W., Concepcion E., Smith E., Jacobson E., et al. Genetically driven target tissue overexpression of CD40: a novel mechanism in autoimmune disease. J. Immunol. 2012, 189:3043-3053.
63. Resetkova E., Kawai K., Enomoto T., Arreaza G., Togun R., Foy T.M., et al. Antibody to gp39, the ligand for CD40 significantly inhibits the humoral response from Graves' thyroid tissues xenografted into severe combined immunodeficient (SCID) mice. Thyroid Off. J. Am. Thyroid Assoc. 1996, 6:267-273.
64. Jacobson E.M., Concepcion E., Oashi T., Tomer Y. A Graves' disease-associated Kozak sequence single-nucleotide polymorphism enhances the efficiency of CD40 gene translation: a case for translational pathophysiology. Endocrinology 2005, 146:2684-2691.
65. Wang P.W., Chen I.Y., Juo S.H., Hsi E., Liu R.T., Hsieh C.J. Genotype and phenotype predictors of relapse of graves' disease after antithyroid drug withdrawal. Eur. Thyroid J. 2013, 1:251-258.
66. Koshy M., Berger D., Crow M.K. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J. Clin. Invest. 1996, 98:826-837.
67. Filion L.G., Matusevicius D., Graziani-Bowering G.M., Kumar A., Freedman M.S. Monocyte-derived IL12, CD86 (B7-2) and CD40L expression in relapsing and progressive multiple sclerosis. Clin. Immunol. 2003, 106:127-138.
68. Danese S., Katz J.A., Saibeni S., Papa A., Gasbarrini A., Vecchi M., et al. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003, 52:1435-1441.
69. Park J.H., Chang H.S., Park C.S., Jang A.S., Park B.L., Rhim T.Y., et al. Association analysis of CD40 polymorphisms with asthma and the level of serum total IgE. Am. J. Respir. Crit. Care Med. 2007, 175:775-782.
70. Fife B.T., Bluestone J.A. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol. Rev. 2008, 224:166-182.
71. Brunner M.C., Chambers C.A., Chan F.K., Hanke J., Winoto A., Allison J.P. CTLA-4-Mediated inhibition of early events of T cell proliferation. J. Immunol. 1999, 162:5813-5820.
72. Vaidya B., Kendall-Taylor P., Pearce S.H. The genetics of autoimmune thyroid disease. J. Clin. Endocrinol. Metab. 2002, 87:5385-5397.
73. Finck B.K., Linsley P.S., Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994, 265:1225-1227.
74. Nishikawa K., Linsley P.S., Collins A.B., Stamenkovic I., McCluskey R.T., Andres G. Effect of CTLA-4 chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis. Eur. J. Immunol. 1994, 24:1249-1254.
75. Knoerzer D.B., Karr R.W., Schwartz B.D., Mengle-Gaw L.J. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J. Clin. Invest. 1995, 96:987-993.
76. Lenschow D.J., Herold K.C., Rhee L., Patel B., Koons A., Qin H.Y., et al. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 1996, 5:285-293.
77. Donner H., Rau H., Walfish P.G., Braun J., Siegmund T., Finke R., et al. CTLA4 alanine-17 confers genetic susceptibility to Graves' disease and to type 1 diabetes mellitus. J. Clin. Endocrinol. Metab. 1997, 82:143-146.
78. Nithiyananthan R., Heward J.M., Allahabadia A., Franklyn J.A., Gough S.C. Polymorphism of the CTLA-4 gene is associated with autoimmune hypothyroidism in the United Kingdom. Thyroid Off. J. Am. Thyroid Assoc. 2002, 12:3-6.
79. Villanueva R., Inzerillo A.M., Tomer Y., Barbesino G., Meltzer M., Concepcion E.S., et al. Limited genetic susceptibility to severe Graves' ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology. Thyroid Off. J. Am. Thyroid Assoc. 2000, 10:791-798.
80. Braun J., Donner H., Siegmund T., Walfish P.G., Usadel K.H., Badenhoop K. CTLA-4 promoter variants in patients with Graves' disease and Hashimoto's thyroiditis. Tissue Antigens 1998, 51:563-566.
81. Yanagawa T., Taniyama M., Enomoto S., Gomi K., Maruyama H., Ban Y., et al. CTLA4 gene polymorphism confers susceptibility to Graves' disease in Japanese. Thyroid Off. J. Am. Thyroid Assoc. 1997, 7:843-846.
82. Tomer Y., Huber A. The etiology of autoimmune thyroid disease: a story of genes and environment. J. Autoimmun. 2009, 32:231-239.
83. Yanagawa T., Hidaka Y., Guimaraes V., Soliman M., DeGroot L.J. CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population. J. Clin. Endocrinol. Metab. 1995, 80:41-45.
84. Kotsa K., Watson P.F., Weetman A.P. A CTLA-4 gene polymorphism is associated with both Graves disease and autoimmune hypothyroidism. Clin. Endocrinol. 1997, 46:551-554.
85. Anjos S., Nguyen A., Ounissi-Benkalha H., Tessier M.C., Polychronakos C. A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J. Biol. Chem. 2002, 277:46478-46486.
86. Ueda H., Howson J.M., Esposito L., Heward J., Snook H., Chamberlain G., et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003, 423:506-511.
87. Jacobson E.M., Huber A., Tomer Y. The HLA gene complex in thyroid autoimmunity: from epidemiology to etiology. J. Autoimmun. 2008, 30:58-62.
88. Ban Y., Davies T.F., Greenberg D.A., Concepcion E.S., Osman R., Oashi T., et al. Arginine at position 74 of the HLA-DR beta1 chain is associated with Graves' disease. Genes Immun. 2004, 5:203-208.
89. Menconi F., Monti M.C., Greenberg D.A., Oashi T., Osman R., Davies T.F., et al. Molecular amino acid signatures in the MHC class II peptide-binding pocket predispose to autoimmune thyroiditis in humans and in mice. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14034-14039.
90. Simmonds M.J., Howson J.M., Heward J.M., Cordell H.J., Foxall H., Carr-Smith J., et al. Regression mapping of association between the human leukocyte antigen region and Graves disease. Am. J. Hum. Genet. 2005, 76:157-163.
91. Muixi L., Carrascal M., Alvarez I., Daura X., Marti M., Armengol M.P., et al. Thyroglobulin peptides associate in vivo to HLA-DR in autoimmune thyroid glands. J. Immunol. 2008, 181:795-807.
92. Sakai K., Shirasawa S., Ishikawa N., Ito K., Tamai H., Kuma K., et al. Identification of susceptibility loci for autoimmune thyroid disease to 5q31-q33 and Hashimoto's thyroiditis to 8q23-q24 by multipoint affected sib-pair linkage analysis in Japanese. Hum. Mol. Genet. 2001, 10:1379-1386.
93. Tomer Y., Ban Y., Concepcion E., Barbesino G., Villanueva R., Greenberg D.A., et al. Common and unique susceptibility loci in Graves and Hashimoto diseases: results of whole-genome screening in a data set of 102 multiplex families. Am. J. Hum. Genet. 2003, 73:736-747.
94. Ban Y., Greenberg D.A., Concepcion E., Skrabanek L., Villanueva R., Tomer Y. Amino acid substitutions in the thyroglobulin gene are associated with susceptibility to human and murine autoimmune thyroid disease. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:15119-15124.
95. Hodge S.E., Ban Y., Strug L.J., Greenberg D.A., Davies T.F., Concepcion E.S., et al. Possible interaction between HLA-DRbeta1 and thyroglobulin variants in Graves' disease. Thyroid Off. J. Am. Thyroid Assoc. 2006, 16:351-355.
96. Jacobson E.M., Yang H., Menconi F., Wang R., Osman R., Skrabanek L., et al. Employing a recombinant HLA-DR3 expression system to dissect major histocompatibility complex II-thyroglobulin peptide dynamism: a genetic, biochemical, and reverse immunological perspective. J. Biol. Chem. 2009, 284:34231-34243.
97. Liu W., Wang H.N., Gu Z.H., Yang S.Y., Ye X.P., Pan C.M., et al. Identification of BACH2 as a susceptibility gene for Graves' disease in the Chinese Han population based on a three-stage genome-wide association study. Hum. Genet. 2014, 133:661-671.
98. Muto A., Hoshino H., Madisen L., Yanai N., Obinata M., Karasuyama H., et al. Identification of Bach2 as a B-cell-specific partner for small maf proteins that negatively regulate the immunoglobulin heavy chain gene 3' enhancer. EMBO J. 1998, 17:5734-5743.
99. Hong S.W., Kim S., Lee D.K. The role of Bach2 in nucleic acid-triggered antiviral innate immune responses. Biochem. Biophys. Res. Commun. 2008, 365:426-432.
100. Zhao S.X., Xue L.Q., Liu W., Gu Z.H., Pan C.M., Yang S.Y., et al. Robust evidence for five new Graves' disease risk loci from a staged genome-wide association analysis. Hum. Mol. Genet. 2013, 22:3347-3362.
101. Menard L., Cantaert T., Chamberlain N., Tangye S.G., Riminton S., Church J.A., et al. Signaling lymphocytic activation molecule (SLAM)/SLAM-associated protein pathway regulates human B-cell tolerance. J. allergy Clin. Immunol. 2014, 133:1149-1161.
102. Chen X.J., Gong X.H., Yan N., Meng S., Qin Q., Jiang Y.F., et al. RNASET2 tag SNP but not CCR6 polymorphisms is associated with autoimmune thyroid diseases in the Chinese Han population. BMC Med. Genet. 2015, 16:11.
103. Szymanski K., Bednarczuk T., Krajewski P., Ploski R. The replication of the association of the rs6832151 within chromosomal band 4p14 with Graves' disease in a Polish Caucasian population. Tissue Antigens 2012, 79:380-383.
104. Brown R.S., Lombardi A., Hasham A., Greenberg D.A., Gordon J., Concepcion E., et al. Genetic analysis in young-age-of-onset Graves' disease reveals new susceptibility loci. J. Clin. Endocrinol. Metab. 2014, 99:E1387-E1391.
105. Simmonds M.J., Heward J.M., Barrett J.C., Franklyn J.A., Gough S.C. Association of the BTNL2 rs2076530 single nucleotide polymorphism with Graves' disease appears to be secondary to DRB1 exon 2 position beta74. Clin. Endocrinol. 2006, 65:429-432.
106. Krikos A., Laherty C.D., Dixit V.M. Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. J. Biol. Chem. 1992, 267:17971-17976.
107. Song R.H., Yu Z.Y., Wang Q., Muhali F.S., Jiang W.J., Xiao L., et al. Polymorphisms of the TNFAIP3 region and Graves' disease. Autoimmunity 2014, 47:459-465.
108. Ban Y., Greenberg D.A., Davies T.F., Jacobson E., Concepcion E., Tomer Y. Linkage analysis of thyroid antibody production: evidence for shared susceptibility to clinical autoimmune thyroid disease. J. Clin. Endocrinol. Metab. 2008, 93:3589-3596.
109. Medici M., Porcu E., Pistis G., Teumer A., Brown S.J., Jensen R.A., et al. Identification of novel genetic Loci associated with thyroid peroxidase antibodies and clinical thyroid disease. PLoS Genet. 2014, 10:e1004123.
110. Tomer Y., Dolan L.M., Kahaly G., Divers J., D'Agostino R.B., Imperatore G., et al. Genome wide identification of new genes and pathways in patients with both autoimmune thyroiditis and type 1 diabetes. J. Autoimmun. 2015, 60:32-39.
111. Jiang Y., Luo L., Gustafson E.L., Yadav D., Laverty M., Murgolo N., et al. Identification and characterization of a novel RF-amide peptide ligand for orphan G-protein-coupled receptor SP9155. J. Biol. Chem. 2003, 278:27652-27657.
112. Chen X., Hu Z., Li W., Wu P., Liu M., Bao L., et al. Synergistic combined effect between CD40-1C>T and CTLA-4+6230G>A polymorphisms in Graves' disease. Gene 2015, 567:154-158.
113. Inal E.E., Rustemoglu A., Inanir A., Ekinci D., Gul U., Yigit S., et al. Associations of rs4810485 and rs1883832 polymorphisms of CD40 gene with susceptibility and clinical findings of Behcet's disease. Rheumatol. Int. 2015, 35:837-843.
114. Vaidya B., Imrie H., Geatch D.R., Perros P., Ball S.G., Baylis P.H., et al. Association analysis of the cytotoxic T lymphocyte antigen-4 (CTLA-4) and autoimmune regulator-1 (AIRE-1) genes in sporadic autoimmune Addison's disease. J. Clin. Endocrinol. Metab. 2000, 85:688-691.
115. Downie-Doyle S., Bayat N., Rischmueller M., Lester S. Influence of CTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary Sjogren's syndrome. Arthritis Rheum. 2006, 54:2434-2440.
116. Lee Y.H., Harley J.B., Nath S.K. CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis. Hum. Genet. 2005, 116:361-367.
117. Huang D., Liu L., Noren K., Xia S.Q., Trifunovic J., Pirskanen R., et al. Genetic association of Ctla-4 to myasthenia gravis with thymoma. J. Neuroimmunol. 1998, 88:192-198.
118. Djilali-Saiah I., Schmitz J., Harfouch-Hammoud E., Mougenot J.F., Bach J.F., Caillat-Zucman S. CTLA-4 gene polymorphism is associated with predisposition to coeliac disease. Gut 1998, 43:187-189.
119. Agarwal K., Jones D.E., Daly A.K., James O.F., Vaidya B., Pearce S., et al. CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. J. Hepatol. 2000, 32:538-541.
120. Song G.G., Lee Y.H. The CTLA-4 and MCP-1 polymorphisms and susceptibility to systemic sclerosis: a meta-analysis. Immunol. Invest. 2013, 42:481-492.
121. Velaga M.R., Wilson V., Jennings C.E., Owen C.J., Herington S., Donaldson P.T., et al. The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. J. Clin. Endocrinol. Metab. 2004, 89:5862-5865.
122. Bottini N., Musumeci L., Alonso A., Rahmouni S., Nika K., Rostamkhani M., et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat. Genet. 2004, 36:337-338.
123. Carlton V.E., Hu X., Chokkalingam A.P., Schrodi S.J., Brandon R., Alexander H.C., et al. PTPN22 genetic variation: evidence for multiple variants associated with rheumatoid arthritis. Am. J. Hum. Genet. 2005, 77:567-581.
124. Kyogoku C., Langefeld C.D., Ortmann W.A., Lee A., Selby S., Carlton V.E., et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am. J. Hum. Genet. 2004, 75:504-507.
125. Chistiakov D.A., Chistiakov A.P. Is FCRL3 a new general autoimmunity gene?. Hum. Immunol. 2007, 68:375-383.
126. Wang X., Yu T., Yan Q., Wang W., Meng N., Li X., et al. Significant association between Fc receptor-like 3 polymorphisms (-1901A>G and -658C>T) and neuromyelitis optica (NMO) susceptibility in the chinese population. Mol. Neurobiol. 2015, Epub ahead of print.
127. Li K., Zhao M., Hou S., Du L., Kijlstra A., Yang P. Association between polymorphisms of FCRL3, a non-HLA gene, and Behcet's disease in a Chinese population with ophthalmic manifestations. Mol. Vis. 2008, 14:2136-2142.
128. Yuan M., Wei L., Zhou R., Bai Q., Wei Y., Zhang W., et al. Four FCRL3 gene polymorphisms (FCRL3_3, _5, _6, _8) confer susceptibility to multiple sclerosis: results from a case-control study. Mol. Neurobiol. 2015, Epub ahead of print.
129. Svejgaard A., Platz P., Ryder L.P. HLA and disease 1982 - a survey. Immunol. Rev. 1983, 70:193-218.
130. Todd J.A., Acha-Orbea H., Bell J.I., Chao N., Fronek Z., Jacob C.O., et al. A molecular basis for MHC class II-associated autoimmunity. Science 1988, 240:1003-1009.